Premium
P4‐406: Tarenflurbil (MPC‐7869), a selective Aβ42‐lowering agent, has no significant effect on drugs metabolized by CYP2C9
Author(s) -
Zavitz Kenton,
Bradford Chad,
Johnson Troy,
Swabb Edward,
Mather Gary
Publication year - 2008
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2008.05.2477
Subject(s) - tolbutamide , tolerability , placebo , medicine , pharmacology , cmax , crossover study , pharmacokinetics , gastroenterology , adverse effect , pathology , alternative medicine , insulin